Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bio-Three H
- Development stage
- Unknown
- Lead developer
- Toa Pharmaceuticals
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
BIO-THREE H is an oral probiotic formulation developed by TOA Biopharma (formerly TOA Pharmaceutical) and distributed by Alinamin Pharmaceutical. It is approved in Japan as a designated quasi-drug for intestinal regulation, constipation, soft stools, and abdominal bloating. The formulation contains three symbiotic active bacterial strains: Clostridium butyricum TO-A (butyric acid bacteria), Enterococcus faecalis T-110 (lactic acid bacteria), and Bacillus mesentericus TO-A (saccharifying bacteria). These three strains work synergistically throughout different sections of the gastrointestinal tract, from the small intestine to the large intestine, to improve the composition of the intestinal microflora, enhance the intestinal barrier function, and support regular bowel movements.
- Brand names
- Bio-Three HビオスリーH
- Other names
- Bio-Three H PowderBio-Three H granulesビオスリーH散
02
Targets
Intestinal microbiota composition and ecologyShigella spp. (Shigella species)
Beyond the preview
Go deeper on Bio-Three H.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bio-Three H.